Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Bempedoic acid & Atherosclerosis / Coronary Artery Disease (CAD) / Coronary Heart Disease (CHD) / Ischemic Heart Disease (IHD)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

Concerning Bempedoic acid & Atherosclerosis / Coronary Artery Disease (CAD) / Coronary Heart Disease (CHD) / Ischemic Heart Disease (IHD), Bempedoic acid is approved by both the FDA and EMA in patients with established atherosclerotic cardiovascular disease (ASCVD), which includes clinical entities such as coronary artery disease and ischemic heart disease (1, 2).

References:

(1) Tummala et al. 2022 Ann Med 54(1): 1287-1296
(2) Biolo et al. 2022 Front Cardiovasc Med 9: 1028355

…

References (Sources)

Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis
Tummala et al. 2022 Ann Med 54(1): 1287-1296
Review
Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome
Biolo et al. 2022 Front Cardiovasc Med 9: 1028355
Review

AI Chat

7/1/2026

Chat with our artificial intelligence: